Autoantibodies against apolipoprotein A-1 after COVID-19 predict symptoms persistence.
COVID-19
anti-apolipoprotein A-1 autoantibodies
long COVID-19
symptoms persistence
type I interferon response
Journal
European journal of clinical investigation
ISSN: 1365-2362
Titre abrégé: Eur J Clin Invest
Pays: England
ID NLM: 0245331
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
25
03
2022
accepted:
19
05
2022
pubmed:
23
5
2022
medline:
15
9
2022
entrez:
22
5
2022
Statut:
ppublish
Résumé
SARS-CoV-2 infection triggers different auto-antibodies, including anti-apolipoprotein A-1 IgGs (AAA1), which could be of concern as mediators of persistent symptoms. We determined the kinetics of AAA1 response over after COVID-19 and the impact of AAA1 on the inflammatory response and symptoms persistence. All serologies were assessed at one, three, six and twelve months in 193 hospital employees with COVID-19. ROC curve analyses and logistic regression models (LRM) were used to determine the prognostic accuracy of AAA1 and their association with patient-reported COVID-19 symptoms persistence at 12 months. Interferon (IFN)-α and-γ production by AAA1-stimulated human monocyte-derived macrophages (HMDM) was assessed in vitro. AAA1 seropositivity was 93% at one month and declined to 15% at 12 months after COVID-19. Persistent symptoms at 12 months were observed in 45.1% of participants, with a predominance of neurological (28.5%), followed by general (15%) and respiratory symptoms (9.3%). Over time, strength of correlations between AAA1 and anti-SARS-COV2 serologies decreased, but remained significant. From the 3 COVID-19 induces a marked though transient AAA1 response, independently predicting one-year persistence of respiratory symptoms. By increasing IFN-α response, AAA1 may contribute to persistent symptoms. If and how AAA1 levels assessment could be of use for COVID-19 risk stratification remains to be determined.
Sections du résumé
BACKGROUND
BACKGROUND
SARS-CoV-2 infection triggers different auto-antibodies, including anti-apolipoprotein A-1 IgGs (AAA1), which could be of concern as mediators of persistent symptoms. We determined the kinetics of AAA1 response over after COVID-19 and the impact of AAA1 on the inflammatory response and symptoms persistence.
METHODS
METHODS
All serologies were assessed at one, three, six and twelve months in 193 hospital employees with COVID-19. ROC curve analyses and logistic regression models (LRM) were used to determine the prognostic accuracy of AAA1 and their association with patient-reported COVID-19 symptoms persistence at 12 months. Interferon (IFN)-α and-γ production by AAA1-stimulated human monocyte-derived macrophages (HMDM) was assessed in vitro.
RESULTS
RESULTS
AAA1 seropositivity was 93% at one month and declined to 15% at 12 months after COVID-19. Persistent symptoms at 12 months were observed in 45.1% of participants, with a predominance of neurological (28.5%), followed by general (15%) and respiratory symptoms (9.3%). Over time, strength of correlations between AAA1 and anti-SARS-COV2 serologies decreased, but remained significant. From the 3
CONCLUSION
CONCLUSIONS
COVID-19 induces a marked though transient AAA1 response, independently predicting one-year persistence of respiratory symptoms. By increasing IFN-α response, AAA1 may contribute to persistent symptoms. If and how AAA1 levels assessment could be of use for COVID-19 risk stratification remains to be determined.
Identifiants
pubmed: 35598178
doi: 10.1111/eci.13818
pmc: PMC9348059
doi:
Substances chimiques
Antibodies, Viral
0
Antiviral Agents
0
Apolipoprotein A-I
0
Autoantibodies
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13818Subventions
Organisme : De Reuter Foundation
ID : 657
Organisme : Fondation Ancrage
Organisme : Fondation de Bienfaisance du Groupe Pictet
Organisme : Fondation Prive des HUG
Organisme : Geneva University Hospitals and Faculty of Medicine's Center for Vaccinology
Organisme : Geneva University Hospitals and Faculty of Medicine's Centre for Emerging Viral Diseases.
Organisme : Geneva University Hospitals Project and Development Grant
Organisme : Schmidheiny Foundation
Informations de copyright
© 2022 The Authors. European Journal of Clinical Investigation published by John Wiley & Sons Ltd on behalf of Stichting European Society for Clinical Investigation Journal Foundation.
Références
Circulation. 2020 May 26;141(21):e823-e831
pubmed: 32228309
Cell Host Microbe. 2016 Feb 10;19(2):181-93
pubmed: 26867177
Eur J Clin Invest. 2022 Oct;52(10):e13818
pubmed: 35598178
Pol Arch Intern Med. 2020 May 29;130(5):400-406
pubmed: 32356642
Ann Rheum Dis. 2020 Dec;79(12):1661-1663
pubmed: 32581086
Hepatol Int. 2018 Jan;12(1):17-25
pubmed: 29423541
J Exp Med. 2021 Jul 5;218(7):
pubmed: 33890986
Nat Rev Immunol. 2020 Oct;20(10):585-586
pubmed: 32788708
EBioMedicine. 2020 May;55:102763
pubmed: 32361250
Eur J Immunol. 2021 Apr;51(4):893-902
pubmed: 33368288
J Infect Dis. 2020 Oct 1;222(9):1439-1443
pubmed: 32738141
Curr Cardiol Rep. 2021 Aug 3;23(9):129
pubmed: 34342728
Nature. 2021 Jul;595(7866):283-288
pubmed: 34010947
Thromb Haemost. 2016 Sep 27;116(4):764-71
pubmed: 27384400
Nature. 2021 Feb;590(7844):29-31
pubmed: 33469204
Endocrinology. 2015 Dec;156(12):4707-19
pubmed: 26393305
J Intern Med. 2012 Oct;272(4):344-57
pubmed: 22329401
J Biol Chem. 2014 Oct 10;289(41):28249-59
pubmed: 25170076
Clin Exp Rheumatol. 2020 Jul-Aug;38(4):754-759
pubmed: 32723434
Sci Immunol. 2020 Jul 10;5(49):
pubmed: 32651212
Exp Lung Res. 2008 Nov;34(9):599-629
pubmed: 19005923
Front Immunol. 2017 Apr 18;8:437
pubmed: 28458671
J Neurol. 2021 Mar;268(3):751-757
pubmed: 32734353
Cell. 2021 Sep 16;184(19):4953-4968.e16
pubmed: 34492226
Clin Transl Immunology. 2020 Dec 14;9(12):e1220
pubmed: 33343896
Curr Opin Infect Dis. 2009 Feb;22(1):49-56
pubmed: 19532080
Clin Microbiol Infect. 2021 Jan 20;:
pubmed: 33482352
Eur J Clin Invest. 2022 Feb;52(2):e13713
pubmed: 34841527
PLoS One. 2015 Jul 15;10(7):e0132780
pubmed: 26177543
J Transl Autoimmun. 2021;4:100100
pubmed: 33880442
Science. 2020 Nov 27;370(6520):
pubmed: 32994364
Science. 2020 May 8;368(6491):630-633
pubmed: 32245784
ACS Cent Sci. 2020 Dec 23;6(12):2238-2249
pubmed: 33372199
Eur J Clin Invest. 2021 Nov;51(11):e13661
pubmed: 34324704
Immunol Lett. 2015 Jan;163(1):56-68
pubmed: 25445494
PLoS One. 2020 Sep 9;15(9):e0238089
pubmed: 32903266
N Engl J Med. 2021 Jun 10;384(23):2202-2211
pubmed: 33861525
J Clin Med. 2019 Jul 09;8(7):
pubmed: 31324073
JAMA. 2021 May 18;325(19):2015-2016
pubmed: 33825846
Cardiovasc Res. 2017 Aug 1;113(10):1102-1112
pubmed: 28899001
Cell Host Microbe. 2020 Apr 8;27(4):671-680.e2
pubmed: 32183941
Arterioscler Thromb Vasc Biol. 2017 Dec;37(12):2342-2349
pubmed: 29074586
Immunity. 2021 May 11;54(5):1083-1095.e7
pubmed: 33891889
J Autoimmun. 2021 Aug;122:102683
pubmed: 34144328
J Infect. 2018 Feb;76(2):186-195
pubmed: 29198606
Nat Commun. 2020 Jun 1;11(1):2806
pubmed: 32483236
Eur J Clin Invest. 2022 Feb;52(2):e13729
pubmed: 34921724
Antibodies (Basel). 2020 Jul 16;9(3):
pubmed: 32708525
Nat Rev Dis Primers. 2016 Jan 14;2:15084
pubmed: 27188830
Eur Heart J. 2010 Apr;31(7):815-23
pubmed: 20176799
J Clin Med. 2019 Jun 29;8(7):
pubmed: 31261925